We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vaxart Inc (VXRT) USD0.01

Sell:$1.23 Buy:$1.25 Change: $0.03 (2.46%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Sell:$1.23
Buy:$1.25
Change: $0.03 (2.46%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Sell:$1.23
Buy:$1.25
Change: $0.03 (2.46%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer.

Contact details

Address:
170 Harbor Way, Suite 300
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 5503500
Website:
https://vaxart.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VXRT
ISIN:
US92243A2006
Market cap:
$218.64 million
Shares in issue:
168.84 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Finney
    Chairman of the Board, Interim Chief Executive Officer
  • Phillip Lee
    Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer
  • Sean Tucker
    Senior Vice President, Chief Scientific Officer
  • Edward Berg
    Senior Vice President, General Counsel
  • Raymond Stapleton
    Chief Technology Officer
  • James Cummings
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.